Skip to main content

Want a detailed portfolio tracker?

RANI
NASDAQ
$0.69

Rani Therapeutics Holdings Inc Class A (RANI)

Rani Therapeutics Holdings Inc. is an innovative biotechnology company transforming the landscape of drug delivery with its proprietary RaniPill™ technology, which enables the oral administration of biologic therapeutics. This groundbreaking approach not only enhances patient adherence but also aligns with the growing preference for non-invasive treatment options. With a robust and diversified pipeline targeting multiple therapeutic areas, Rani Therapeutics is strategically positioned for significant growth. The company’s commitment to cutting-edge research and development, along with key partnerships, further underscores its potential to make impactful advancements in the pharmaceutical sector.
Website: https://www.ranitherapeutics.com
Sector:
Healthcare
Industry:
Biotechnology
68 analysts
Strong Buy
Target: $7.50 (+992.82%)

Market Cap

$122M

Revenue 5Y CAGR

+21.08%

Free Cash Flow Yield

-14.04%

Beta (5Y)

2.23

Price Chart

Valuation
Market Cap$122M
P/S29.37
P/B2.54
Profitability
Total Revenue (TTM)$3.17M
Gross Profit (TTM)$3.17M
EBITDA-$34M
Operating Margin-488.2%
EPS-$0.56
Financial Health
Free Cash Flow Yield-14.04%
Growth & Risk
Revenue 5Y CAGR+21.08%
Beta (5Y)2.23
Sharpe Ratio0.83